SMT201600156B - Trattamento dell’osteoartrite - Google Patents

Trattamento dell’osteoartrite

Info

Publication number
SMT201600156B
SMT201600156B SM201600156T SM201600156T SMT201600156B SM T201600156 B SMT201600156 B SM T201600156B SM 201600156 T SM201600156 T SM 201600156T SM 201600156 T SM201600156 T SM 201600156T SM T201600156 B SMT201600156 B SM T201600156B
Authority
SM
San Marino
Prior art keywords
osteoartritis
treatment
Prior art date
Application number
SM201600156T
Other languages
English (en)
Italian (it)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600156(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of SMT201600156B publication Critical patent/SMT201600156B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
SM201600156T 2008-12-22 2016-06-01 Trattamento dell’osteoartrite SMT201600156B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (1)

Publication Number Publication Date
SMT201600156B true SMT201600156B (it) 2016-08-31

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600156T SMT201600156B (it) 2008-12-22 2016-06-01 Trattamento dell’osteoartrite

Country Status (19)

Country Link
US (4) US9243061B2 (enExample)
EP (2) EP2376121B2 (enExample)
JP (3) JP5727379B2 (enExample)
KR (2) KR101898982B1 (enExample)
CN (2) CN102271705A (enExample)
AU (1) AU2009329814B2 (enExample)
BR (1) BRPI0918356B1 (enExample)
CA (1) CA2746827C (enExample)
CY (1) CY1117698T1 (enExample)
DK (1) DK2376121T4 (enExample)
ES (2) ES2572368T5 (enExample)
HK (1) HK1226938A1 (enExample)
HR (1) HRP20160577T4 (enExample)
HU (1) HUE028615T2 (enExample)
PL (1) PL2376121T5 (enExample)
RU (2) RU2011127334A (enExample)
SI (2) SI2376121T2 (enExample)
SM (1) SMT201600156B (enExample)
WO (1) WO2010071924A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5674677B2 (ja) 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
KR101898982B1 (ko) 2008-12-22 2018-09-14 더 유니버시티 오브 멜버른 골관절염 치료
CN109999195A (zh) 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
JOP20200031A1 (ar) * 2017-08-14 2020-02-12 Zynerba Pharmaceuticals Inc طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
CA2064814C (en) 1989-08-11 2004-06-08 Nicos Anthony Nicola Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
JP2005507915A (ja) * 2001-10-26 2005-03-24 ノバルティス アクチエンゲゼルシャフト 変形性関節症の処置方法およびその組成物
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
JP2008505054A (ja) † 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
ES2465141T3 (es) * 2004-03-31 2014-06-05 Kazuwa Nakao Remedio o medicamento preventivo para la artritis
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
WO2006023412A2 (en) 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
NZ564027A (en) † 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007063311A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
ES2609088T3 (es) * 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
EP1999152B1 (en) 2006-03-27 2012-09-19 Medimmune Limited Binding member for gm-csf receptor
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
CA2687791A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
US20090163440A1 (en) * 2007-09-26 2009-06-25 Waddell David D Ion-Channel Regulator Compositions and Methods of Using Same
WO2009062238A1 (en) 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
ME01005B (me) * 2007-11-13 2012-10-20 Boehringer Ingelheim Int MONOKLONSKA ANTITIJELA KOJA SE VEZUJU ZA HGM-CSF l MEDICINSKI PREPARATI KOJI IH SADRŽE
EP2271671A2 (en) † 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
DK2280732T3 (en) * 2008-04-28 2019-01-28 Humanigen Inc ANTIBODIES AGAINST GRANULOCYT MACROPHAG COLONY STIMULATING FACTOR
KR101898982B1 (ko) 2008-12-22 2018-09-14 더 유니버시티 오브 멜버른 골관절염 치료
JP5674677B2 (ja) † 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

Also Published As

Publication number Publication date
EP3056217A1 (en) 2016-08-17
RU2016102339A3 (enExample) 2019-07-29
CN106397591A (zh) 2017-02-15
AU2009329814A1 (en) 2010-07-01
CY1117698T1 (el) 2017-05-17
ES2572368T3 (es) 2016-05-31
US20120003234A1 (en) 2012-01-05
ES2886063T3 (es) 2021-12-16
RU2712273C2 (ru) 2020-01-28
KR101799264B1 (ko) 2017-11-20
RU2016102339A (ru) 2018-11-21
AU2009329814B2 (en) 2015-06-18
SI2376121T2 (sl) 2021-11-30
EP3056217B1 (en) 2021-06-30
CA2746827A1 (en) 2010-07-01
DK2376121T4 (da) 2021-08-16
JP2012512815A (ja) 2012-06-07
JP5727379B2 (ja) 2015-06-03
ES2572368T5 (es) 2021-12-16
HUE028615T2 (en) 2016-12-28
US9243061B2 (en) 2016-01-26
EP2376121A1 (en) 2011-10-19
US20200247895A1 (en) 2020-08-06
BRPI0918356B1 (pt) 2022-03-08
JP2015143233A (ja) 2015-08-06
EP2376121B2 (en) 2021-06-09
JP2017200933A (ja) 2017-11-09
US20160185868A1 (en) 2016-06-30
EP2376121B1 (en) 2016-03-09
PL2376121T3 (pl) 2016-12-30
US20180066062A1 (en) 2018-03-08
CN102271705A (zh) 2011-12-07
KR101898982B1 (ko) 2018-09-14
CA2746827C (en) 2018-01-23
BRPI0918356A2 (pt) 2020-10-06
HRP20160577T4 (hr) 2021-08-20
HK1226938A1 (en) 2017-10-13
WO2010071924A1 (en) 2010-07-01
RU2011127334A (ru) 2013-01-27
EP2376121A4 (en) 2013-04-03
PL2376121T5 (pl) 2021-09-27
SI2376121T1 (sl) 2016-07-29
JP6458086B2 (ja) 2019-01-23
KR20170128630A (ko) 2017-11-22
KR20110128273A (ko) 2011-11-29
DK2376121T3 (en) 2016-05-30
HRP20160577T1 (hr) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
BRPI0916931A2 (pt) agentes terapêuticos
DK2222272T3 (da) Behandling af luftvejssygdom
PT2448582T (pt) Compostos e composições terapêuticas
PL2405869T3 (pl) Leczenie otyłości
HUE043326T2 (hu) Akut limfoblasztos leukémia kezelése
PL2506850T3 (pl) Sposoby podawania terapii pirfenidonem
BRPI0910854A2 (pt) métodos de tratamento
DK2330887T3 (da) Behandlingsindretning
GB0818074D0 (en) Treatment of biofilms
EP2310006A4 (en) CANCER TREATMENT
SMT201600156B (it) Trattamento dell’osteoartrite
ME03508B (me) Kombinovana terapija za liječenje dijabetesa
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
DK2252317T3 (da) Behandling af makuladegeneration
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
EP3381471C0 (en) PAIN TREATMENT
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
DK2501381T3 (da) Behandling af atrieflimmer
CU23884B1 (es) Derivados de dibenzotiazepina
BRPI0915761A2 (pt) composto de heterociclila para tratamento de doença cardiovascular
DK2173197T3 (da) Fremgangsmåde
FR2930723B1 (fr) Orthese de cheville